Drug intelligence / Profile preview

DU-325

Development stage: Unknown
Lead developer: Avidin
Modality: Small Molecules

Overview

DU-325 is a small molecule dual kinase inhibitor developed by Avidin Biotech, currently in Phase I clinical development for the treatment of leukemia, specifically Acute Myeloid Leukemia (AML). It acts as a potent inhibitor of Janus kinase 2 (JAK2) and FMS-like tyrosine kinase 3 (FLT3), two signaling proteins frequently dysregulated in hematological malignancies. By blocking the activity of these kinases, DU-325 disrupts downstream signaling pathways essential for the proliferation and survival of malignant cells. The compound was identified through Avidin's drug discovery platform and is being evaluated for its safety and preliminary efficacy in patients with advanced leukemia.

Targets

FLT3 (Fms related receptor tyrosine kinase 3)JAK2 (Janus kinase 2)

Beyond the preview

Go deeper on DU-325.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DU-325.

Explore the full profile